Nuclear hormone receptors as therapeutic targets

Contributions to Nephrology

Volumn 170, Issue , 2011, Pages 209-216

  Levi, Moshe ^a   Wang, Xiaoxin ^a   Choudhury, Devasmita ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL RECEPTOR; CELL RECEPTOR; FARNESOID X RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

ARTICLE; DIABETIC NEPHROPATHY; DRUG POTENTIATION; HUMAN; PHYSIOLOGY;

DIABETIC NEPHROPATHIES; HUMANS; RECEPTORS, CALCITRIOL; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 79959281619     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000325668     Document Type: Article

References (37)

1. Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius FC 3rd: From fibrosis to sclerosis: Mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 2008;57:1439-1445.
2. Forbes JM, Coughlan MT, Cooper ME: Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57:1446-1454.
3. Zhu Y, Usui HK, Sharma K: Regulation of transforming growth factor beta in diabetic nephropathy: Implications for treatment. Semin Nephrol 2007;27:153-160. (Pubitemid 46553714)
4. Gurley SB, Coffman TM: The reninangiotensin system and diabetic nephropathy. Semin Nephrol 2007;27:144-152.
5. Weinberg JM: Lipotoxicity. Kidney Int 2006;70:1560-1566. (Pubitemid 44606990)
6. Kimmelstiel P, Wilson C: Intercapillary lesions in the glomeruli of the kidney. Am J Pathol 1936;12:83-98.
7. Wilens SL, Elster SK: The role of lipid deposition in renal arteriolar sclerosis. Am J Med Sci 1950;219:183-196.
8. Sun L, Halaihel N, Zhang W, Rogers T, Levi M: Role of sterol regulatory elementbinding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 2002;277:18919-18927. (Pubitemid 34952453)
9. Proctor G, Jiang T, Iwahashi M, Wang Z, Li J, Levi M: Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 2006;55:2502-2509. (Pubitemid 44871150)
10. Jiang T, Wang Z, Proctor G, Moskowitz S, Liebman SE, Rogers T, et al: Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem 2005;280:32317-32325. (Pubitemid 41361841)
11. Wang Z, Jiang T, Li J, Proctor G, McManaman JL, Lucia S, et al: Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 2005;54: 2328-2335. (Pubitemid 41134259)
12. Plum LA, DeLuca HF: Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 2010;9:941-955.
13. Haussler MR, Haussler CA, Bartik L, Whitfield GK, Hsieh JC, Slater S, et al: Vitamin D receptor: Molecular signaling and actions of nutritional ligands in disease prevention. Nutr Rev 2008;66(suppl 2):S98-S112.
14. Ordonez-Moran P, Munoz A: Nuclear receptors: Genomic and non-genomic effects converge. Cell Cycle 2009;8:1675-1680.
15. Tan X, Wen X, Liu Y: Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 2008;19:1741-1752.
16. Zhang Y, Kong J, Deb DK, Chang A, Li YC: Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 2010;21:966-973.
17. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, et al: Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74:1394-1402.
18. Kong J, Qiao G, Zhang Z, Liu SQ, Li YC: Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int 2008;74:1577-1581.
19. Deb DK, Chen Y, Zhang Z, Zhang Y, Szeto FL, Wong KE, et al: 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-kappaB pathway. Am J Physiol Renal Physiol 2009;296:F1212-F1218.
20. Tan X, Li Y, Liu Y: Therapeutic role and potential mechanisms of active vitamin D in renal interstitial fibrosis. J Steroid Biochem Mol Biol 2007;103:491-496. (Pubitemid 46401277)
21. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, et al: Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008;73:163-171.
22. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, et al: Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18:1796-1806. (Pubitemid 46870316)
23. Deb DK, Sun T, Wong KE, Zhang Z, Ning G, Zhang Y, et al: Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 2010;77:1000-1009.
24. Wang XX, Jiang T, Shen Y, Santamaria H, Solis N, Arbeeny CM, et al: The vitamin D receptor agonist doxercalciferol modulates dietary fat induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol 2011, Epub ahead of print.
25. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, et al: Vitamin D receptor as an intestinal bile acid sensor. Science 2002;296:1313-1316. (Pubitemid 34522785)
26. Schmidt DR, Holmstrom SR, Fon Tacer K, Bookout AL, Kliewer SA, Mangelsdorf DJ: Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol Chem 2010;285:14486-14494.
27. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 2010;376:1543-1551.
28. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al: Identification of a nuclear receptor for bile acids. Science 1999;284:1362-1365. (Pubitemid 29289663)
29. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, et al: Bile acids: Natural ligands for an orphan nuclear receptor. Science 1999;284: 1365-1368. (Pubitemid 29289664)
30. Wang H, Chen J, Hollister K, Sowers LC, Forman BM: Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999;3:543-553. (Pubitemid 29268438)
31. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ: Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006;126:789-799. (Pubitemid 44233630)
32. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K: Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008;7:678-693.
33. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B: Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89:147-191.
34. Miyazaki-Anzai S, Levi M, Kratzer A, Ting TC, Lewis LB, Miyazaki M: Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/-mice with chronic kidney disease. Circ Res 2010;106:1807-1817.
35. Jiang T, Wang XX, Scherzer P, Wilson P, Tallman J, Takahashi H, et al: Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 2007;56:2485-2493. (Pubitemid 47523255)
36. Wang XX, Jiang T, Shen Y, Caldas Y, Miyazaki-Anzai S, Santamaria H, et al: Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes 2010;59:2916-2927.
37. Wang XX, Jiang T, Shen Y, Adorini L, Pruzanski M, Gonzalez FJ, et al: The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol 2009;297:F1587-F1596.